Logo

Amsbio Circulating Tumor DNA Reference Standards

Sep 18, 2018

Amsbio has launched a new range of circulating tumor DNA reference standards: a set of highly characterized, quantitative multiplex quality controls to support the development of new assays. The standards are engineered to mimic the fragmentation profile of nucleosomal ctDNA (aproximately 166 bp) observed in real patient samples across a range of allele frequencies. Pre-validated by digital PCR, the kits include cancer-associated mutations in EGFR, PIK3CA, NRAS and KRAS, and are available as purified DNA or in a synthetica plasma.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.